Agios Historical Income Statement
| AGIO Stock | USD 58.66 0.44 0.74% |
Historical analysis of Agios Pharm income statement accounts such as Interest Expense of 15.4 M, Selling General Administrative of 81.2 M or Total Revenue of 25.5 M can show how well Agios Pharm performed in making a profits. Evaluating Agios Pharm income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Agios Pharm's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Agios Pharm latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Agios Pharm is a good buy for the upcoming year.
Agios |
About Agios Income Statement Analysis
Agios Pharm Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Agios Pharm shareholders. The income statement also shows Agios investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Agios Pharm Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Agios Pharm generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Agios Pharm. It is also known as Agios Pharm overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Agios Pharm's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Agios Pharm current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.At this time, Agios Pharm's Reconciled Depreciation is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 836K | 12.8M | 14.7M | 15.4M | Depreciation And Amortization | 18.8M | 18.6M | 6.6M | 8.3M |
Agios Pharm income statement Correlations
Click cells to compare fundamentals
Agios Pharm Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Agios Pharm income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 8.1M | 18.8M | 18.8M | 18.6M | 6.6M | 8.3M | |
| Interest Expense | 14.9M | 17.8M | 836K | 12.8M | 14.7M | 15.4M | |
| Selling General Administrative | 132.0M | 149.1M | 121.4M | 121.7M | 119.9M | 81.2M | |
| Total Revenue | 117.9M | 203.2M | 41.4K | 14.2M | 26.8M | 25.5M | |
| Gross Profit | 116.6M | 200.4M | (18.8M) | 12.5M | 17.3M | 16.5M | |
| Other Operating Expenses | 544.2M | 519.3M | 378.4M | 403.3M | 418.3M | 321.8M | |
| Operating Income | (426.3M) | (316.1M) | (378.4M) | (389.0M) | (391.5M) | (371.9M) | |
| Ebit | (426.3M) | (344.9M) | (356.5M) | (399.0M) | (391.5M) | (371.9M) | |
| Research Development | 410.9M | 367.5M | 257.0M | 279.9M | 288.9M | 239.2M | |
| Ebitda | (418.2M) | (326.1M) | (337.7M) | (380.5M) | (384.9M) | (365.6M) | |
| Cost Of Revenue | 1.3M | 2.8M | 18.8M | 1.7M | 9.5M | 9.0M | |
| Total Operating Expenses | 542.9M | 516.5M | 378.4M | 401.6M | 408.8M | 320.4M | |
| Income Before Tax | (411.5M) | (327.4M) | (356.5M) | (231.8M) | (352.1M) | (334.5M) | |
| Total Other Income Expense Net | 14.9M | 6.6M | 21.9M | 157.2M | 39.4M | 22.6M | |
| Net Income | (396.6M) | (335.2M) | 1.6B | (74.6M) | (352.1M) | (334.5M) | |
| Income Tax Expense | (14.9M) | 7.8M | (2.0B) | (157.2M) | 6.5M | 6.8M | |
| Net Income From Continuing Ops | (411.5M) | (309.5M) | (356.5M) | (231.8M) | (352.1M) | (369.7M) | |
| Non Operating Income Net Other | 14.9M | 6.6M | 21.9M | 29.4M | 33.8M | 35.5M | |
| Net Income Applicable To Common Shares | (411.5M) | (327.4M) | 1.6B | (231.8M) | (266.6M) | (253.2M) | |
| Interest Income | 14.9M | 6.6M | 836K | 12.8M | 33.3M | 35.0M | |
| Net Interest Income | 14.9M | (11.2M) | 836K | 12.8M | 33.3M | 35.0M | |
| Reconciled Depreciation | 8.1M | 10.0M | 9.2M | 8.6M | 6.6M | 8.8M |
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Agios Stock
Moving against Agios Stock
| 0.8 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.73 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.73 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.73 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.71 | RDY | Dr Reddys Laboratories | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.